Catalyst Pharmaceuticals (CPRX) Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Elanco Animal Health (NYSE:ELAN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Do analysts rate CPRX or ELAN?

Catalyst Pharmaceuticals currently has a consensus target price of $33.20, suggesting a potential upside of 61.56%. Elanco Animal Health has a consensus target price of $19.14, suggesting a potential downside of 10.65%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Catalyst Pharmaceuticals is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Elanco Animal Health	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.91

Does the media favor CPRX or ELAN?

In the previous week, Elanco Animal Health had 8 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 9 mentions for Elanco Animal Health and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.17 beat Elanco Animal Health's score of 0.64 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Elanco Animal Health	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals hold more shares of CPRX or ELAN?

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 97.5% of Elanco Animal Health shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of Elanco Animal Health shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is CPRX or ELAN more profitable?

Catalyst Pharmaceuticals has a net margin of 37.36% compared to Elanco Animal Health's net margin of 9.68%. Catalyst Pharmaceuticals' return on equity of 40.78% beat Elanco Animal Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.36%	40.78%	35.36%
Elanco Animal Health	9.68%	7.04%	3.45%

Which has more volatility and risk, CPRX or ELAN?

Catalyst Pharmaceuticals has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Elanco Animal Health has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500.

Which has stronger earnings and valuation, CPRX or ELAN?

Elanco Animal Health has higher revenue and earnings than Catalyst Pharmaceuticals. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$558.50M	4.50	$163.89M	$1.65	12.45
Elanco Animal Health	$4.44B	2.40	$338M	$0.86	24.91

Summary

Catalyst Pharmaceuticals beats Elanco Animal Health on 9 of the 16 factors compared between the two stocks.